Table 1.
Treatment efficacy with nivolumab plus ipilimumab as first-line treatment in advanced NSCLC patients
| Trial | Treatment dose | N | RR (%) | PFS (mo.) | OS (mo.) | Grade ≥3 AE (%) |
|---|---|---|---|---|---|---|
| CheckMate 01246,50 | Nivo 3 Q2W + Ipi 1 Q12W | 38 | 47 | 8.1 | 2-year OS: 56% | 37 |
| Nivo 3 Q2W + Ipi 1 Q6W | 40 | 38 | 3.9 | 2-year OS: 42% | 33 | |
| CheckMate 56814 | Nivo 3 Q2W + Ipi 1 Q6W | 288 | 30 | Note reported | Not reported | 29 |
| CheckMate 2279 | Nivo 3 Q2W + Ipi 1 Q6W | 139 | 45.3 | 7.2 | 23.3 | 31 |
| CheckMate 81754 * | Nivo 240 mg Q2W+Ipi 1 Q6W | 391 | 35 | 6.1 | Not reported | 35 |
Notes: Doses of Nivolumab (Nivo.) and Ipilimumab (Ipi.) are mg/kg. Q2W/Q6W/Q12W: Every 2/6/12 weeks. *Cohort A.
Abbreviations: AE, OS, overall survival; PFS, progression-free survival; RR, response rate.